Chronic kidney failure
Drug research and approvals for chronic kidney failure: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 527 studies of chronic kidney failure are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 527
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Six-Channel Wearable ECG for Prediction of Hyperkalemia in Hemodialysis PatientsNCT07947485 · Not reported · Chungnam National University Hospital · starts Nov 12, 2026
- RDN for CKD and Uncontrolled Hypertension TrialNCT07945795 · Not applicable · Beijing Anzhen Hospital · starts Dec 8, 2025
- Observational Study to Evaluate the Safety and Efficacy of Kremezin IDT/Fine Gran in Progressive Chronic Kidney Disease…NCT07930169 · Not reported · HK inno.N Corporation · starts Jul 18, 2023
- Nurse-Led Interventions Addressing Physical Exercise and Psychological Needs on Enhancing Outcomes in Patients With…NCT07927660 · Not applicable · Menoufia University · starts Feb 1, 2026
- A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney…NCT07916181 · Phase 1 · Basilea Pharmaceutica · starts Oct 27, 2026
- Kidney Stiffness Measured by Ultrasound in Patients With High Blood Pressure and Healthy VolunteersNCT07914075 · Not reported · Azienda Ospedaliera di Padova · starts Aug 11, 2026
- Effect of Synbiotic Therapy on Renal Function Outcomes in Patients With Chronic Kidney Disease Stage III-IV: A…NCT07912359 · Not applicable · Chittagong Medical College · starts Oct 11, 2026
- Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney DiseaseNCT07911124 · Phase 2 · University of Arkansas · starts Nov 1, 2026
- Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot TrialNCT07910773 · Not applicable · University of California, San Francisco · starts Oct 30, 2026
Approved 24 of 28
- Lanthanum carbonatePhosphate sequestering agent
- Epoetin alfaErythropoietin receptor agonist
- Epoetin betaErythropoietin receptor agonist
- Darbepoetin alfaErythropoietin receptor agonist
- IrbesartanType-1 angiotensin II receptor antagonist
- Folic acid
- LosartanType-1 angiotensin II receptor antagonist
- Ferumoxytol
- ChlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- HydrochlorothiazideThiazide-sensitive sodium-chloride cotransporter inhibitor
- ChlorthalidoneThiazide-sensitive sodium-chloride cotransporter inhibitor
- CalcitriolVitamin D receptor agonist
- OseltamivirNeuraminidase inhibitor
- Ceftaroline fosamilBacterial penicillin-binding protein inhibitor
- RoxadustatHypoxia-inducible factor prolyl hydroxylase inhibitor
- Ascorbic acidSupplement
- Epoetin zetaErythropoietin receptor agonist
- Epoetin deltaErythropoietin receptor agonist
- Methoxy polyethylene glycol-epoetin betaErythropoietin receptor agonist
- Epoetin thetaErythropoietin receptor agonist
- Thiamine ionSupplement
- PyridoxineSupplement
- CyanocobalaminSupplement
- Biotin
Phase 3 12 of 29
- FermagatePhosphate sequestering agent
- BelataceptT-lymphocyte activation antigen CD86 inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- SirolimusFK506-binding protein 1A inhibitor
- PrednisoneGlucocorticoid receptor agonist
- Sevelamer
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- AcetylcysteineGlutathione precursor
- CyclosporineCyclophilin A modulator
- EverolimusFK506-binding protein 1A inhibitor
- MetoprololBeta-1 adrenergic receptor antagonist
Phase 2 12 of 15
- TolvaptanVasopressin V2 receptor antagonist
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- HeparinAntithrombin-III activator
- AlemtuzumabCAMPATH-1 antigen inhibitor
- RituximabB-lymphocyte antigen CD20 binding agent
- FenoldopamDopamine D1 receptor agonist
- SapropterinPhenylalanine-4-hydroxylase activator
- CyclophosphamideDNA inhibitor
- EmpagliflozinSodium/glucose cotransporter 2 inhibitor
- LunacalcipolVitamin D receptor agonist
- TabalumabTumor necrosis factor ligand superfamily member 13B inhibitor
- SiplizumabT-cell surface antigen CD2 inhibitor
Phase 1 or earlier 12 of 13
- MitomycinDNA inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- EfalizumabIntegrin alpha-L/beta-2 (LFA-1) inhibitor
- NalfurafineKappa opioid receptor agonist
- ApabetaloneBromodomain and extra-terminal motif (BET) inhibitor
- AlisporivirCyclophilin A inhibitor
- PimodivirPolymerase basic protein 2 inhibitor
- AdomeglivantGlucagon receptor antagonist
- EfinopegdutideGlucagon-like peptide 1 receptor agonist
- IcodextrinOsmotic agent
- Fesomersen
How its trials ended
1,934 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 398 whose ending is known, 42% met their primary endpoint, 8% missed it and 50% stopped early.
- Completed, result not reported98351%
- Status unknown29315%
- Ongoing26013%
- Met its primary endpoint1679%
- Stopped: other or unclear1146%
- Stopped: enrollment or feasibility462%
- Missed its primary endpoint312%
- Stopped: sponsor or business decision151%
- Stopped: funding131%
- Stopped: lack of efficacy101%
- Stopped: safety2<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA